Regulatory and ClinicalFDA Meeting GrantedAug 31, 2026 · 8:04am ET
CVKDCadrenal Therapeutics, Inc.
Cadrenal Therapeutics Receives Positive FDA Type D Meeting Outcome for CAD-1005 Phase 3 Study
The FDA meeting supports the design of the Phase 3 registration study.
